Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Mayo Clinic; Vela Diagnostics; MNG Laboratories; and More

NEW YORK (GenomeWeb) – The Mayo Clinic Center for Individualized Medicine said this week that its biorepository has earned accreditation from the College of American Pathologists (CAP). CAP requires proof of high levels of accuracy in collecting, processing, and storing blood and tissue samples, Mayo Clinic said. The accreditation ensures that the biorepository is in line with international best practice guidelines for handling such samples.

Vela Diagnostics announced this week that its Sentosa SX cell-free DNA (cfDNA) Extraction Kit is available through an early-access program for use in next-generation sequencing and real-time PCR workflows. The kit is designed to run on the Sentosa SX101 instrument, and is currently undergoing final validation studies with clinical plasma samples.

MNG Laboratories announced this week that it has received CAP accreditation. CAP's inspection of the lab included examinations of its quality controls, records, staff qualifications, equipment, safety programs, and overall management. Chief Medical Officer Peter Nagy added that the accreditation will enable the company to continue expanding its lineup of genetic and neurochemical testing services.

Rx30 said this week that it has partnered with Alpha Genomix Laboratories to bring an actionable pharmacogenetic platform to market to allow pharmacists and physicians to work together to treat patients. 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.